[1]
Lewis, K.D., Peris, K., Sekulic, A., Stratigos, A.J., Dunn, L., Eroglu, Z., Chang, A.L.S., Migden, M.R., Yoo, S.-Y., Mohan, K., Coates, E., Okoye, E., Baurain, J.-F., Bechter, O., Hauscild, A., Butler, M.O., Hernandez-Aya, L., Licitra, L., Neves, R.I., Ruiz, E.S., Seebach, F., Lowy, I., Goncalves, P. and Fury, M.G. 2023. Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s177. DOI:https://doi.org/10.25251/skin.7.supp.177.